Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Gregg

Sacramento, CA Medical Doctor

NPI 1689657918 CMS profile 1295114

4400 V St, Pathology Building, Sacramento, CA 95817

Open in the dashboard

General payments

$916,304

866 records reported · program years 2019–2025

Research payments

$1,155

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$182,357 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Jeffrey Gregg of Sacramento, CA is reported in the CMS Open Payments database as having received $916,304 across 866 general payments and $1,155 in research payments paid to them. Separately, studies naming them as principal investigator received $182,357 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $38,420 40
2024 General $65,127 62
2023 General $169,005 155
2022 General $140,147 143
2021 General $161,245 158
2020 General $148,258 131
2019 General $194,103 177
2019 Research $1,155 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Gregg
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to Jeffrey Gregg were reported at $38,420. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year Jeffrey Gregg California median Middle half National median
2019 $194,103 $161 $50–$652 $163
2020 $148,258 $114 $34–$392 $114
2021 $161,245 $137 $41–$509 $132
2022 $140,147 $152 $48–$573 $149
2023 $169,005 $162 $50–$581 $160
2024 $65,127 $162 $52–$583 $164
2025 $38,420 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $817,541 751 payments
  2. Blueprint Medicines Corporation $62,330 74 payments
  3. E.R. Squibb & Sons, L.L.C. $18,806 25 payments
  4. Novartis Pharmaceuticals Corporation $8,925 7 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $3,685 2 payments
  6. Roche Diagnostics Corporation $2,400 1 payment
  7. Roche Sequencing Solutions, Inc. $1,500 1 payment
  8. Bayer HealthCare Pharmaceuticals Inc. $842 1 payment
  9. Foundation Medicine, Inc. $136 2 payments
  10. Eli Lilly and Company $95 1 payment
  11. Other $44 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $634,685 191 payments
  2. Travel and Lodging $144,594 361 payments
  3. Consulting Fee $64,790 25 payments
  4. Honoraria $50,843 15 payments
  5. Food and Beverage $20,893 273 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $500 1 payment
Products named General payments · program years 2019–2025
  1. TAGRISSO $550,496 490 payments
  2. LYNPARZA $156,664 141 payments
  3. GAVRETO $58,223 68 payments
  4. IMFINZI Oncology $42,545 42 payments
  5. IMFINZI Cardiovascular And Metabolism $10,075 9 payments
  6. PIQRAY $6,612 4 payments
  7. AYVAKIT $4,107 6 payments
  8. EXKIVITY $3,685 2 payments
  9. AVENIO Millisect $2,400 1 payment
  10. BYL719 $1,710 1 payment
  11. Other $4,087 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,155 1 payment

Records

867 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record